<DOC>
	<DOCNO>NCT02621606</DOCNO>
	<brief_summary>The purpose open-label , 3-part study investigate safety efficacy [ 11C ] MK-6884 Positron Emission Tomography ( PET ) image agent quantify muscarinic 4 ( M4 ) positive allosteric modulator ( PAM ) receptor density brain region interest . The study enroll healthy participant ( Parts I II ) participants Alzheimer 's Disease ( AD ) ( Part III ) . The primary efficacy hypothesis average intra-subject test-retest ( T-RT ) variability tracer uptake brain region interest ≤20 % .</brief_summary>
	<brief_title>11CMK-6884 Positron Emission Tomography ( PET ) Tracer Validation Trial ( MK-6884-001 )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Part I , II III : Male , nonpregnant nonbreast feed female 18 55 year age ( Part I ) 55 85 year age ( Parts II III ) ; addition : Male participant sexually active female childbearing potential must willing use condom first dose study drug 3 month post last dose study drug Female participant reproductive potential must serum βhuman chorionic gonadotropin ( βhCG ) test result consistent nonpregnant state screening agree use two acceptable method birth control begin screen visit , study 2 week last dose study drug Female participant nonchildbearing potential must postmenopausal female ( participant without menses least 1 year follicle stimulate hormone [ FSH ] level postmenopausal range screen ) , surgically sterile female ( status post hysterectomy , oophorectomy , tubal ligation ) Body Mass Index ( BMI ) ≤35 kg/m^2 , height ≤195 cm weight ≤136 kg In good health ( Part I ) generally healthy ( Parts II III ) base medical history , physical examination , vital sign measurement electrocardiogram ( ECG ) Nonsmoker and/or use nicotine nicotinecontaining product least approximately 3 month Part II Only : Willing allow placement arterial catheter radial artery Mini Mental Status Examination ( MMSE ) score ≥27 No history subjective memory cognitive complaint No objective evidence memory cognitive impairment Part III Only : Moderate severe AD define : MMSE score ≤20 Meets National Institute Neurological Communicative Diseases Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criteria probable AD Meets Diagnostic Statistical Manual Mental Disorders , 5th Edition ( DSMV ) criteria AD RosenModified Hachinski score ≤4 Screening magnetic resonance imaging ( MRI ) scan consistent diagnosis AD Clear history cognitive functional decline ≥1 year On stable dose one protocoldefined acetylcholinesterase inhibitor ( AChEIs ) ( i.e. , donepezil rivastigmine ) symptomatic treatment AD . Dose must stable least last 4 week screen Has reliable trial partner/caregiver able accompany participant clinic visit , need , able provide information study investigator/staff via telephone contact Part I , II III : Mentally legally incapacitate , significant emotional problem time screen visit expect conduct trial history clinically significant psychiatric disorder last 5 year , except ( Part III ) psychiatric disorder associate AD History clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary major neurological abnormality disease , unless ( Part II III ) adequately control stable medication regimen History cancer History significant multiple and/or severe allergy anaphylactic reaction significant intolerability prescription nonprescription drug food . For Part II , include know allergy lidocaine may use anesthetic placement arterial catheter Has positive test result hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) Has major surgery donate lose 1 unit blood ( approximately 500 mL ) within 4 week prior screen Has participate another investigational trial within 4 week screen Corrected QT ( QTc ) interval ≥470 msec ( male ) ≥480 msec ( female ) Is unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy , begin approximately 2 week prior administration initial dose study drug throughout study . Consumes &gt; 3 serving alcohol day Consumes &gt; 6 caffeine serving day Is currently regular recreational user cannabis , illicit drug history drug ( include alcohol ) abuse within approximately 3 month Has participate PET research study study involve administration radioactive substance ionize radiation within 12 month prior screen undergone extensive radiological examination within period Suffers claustrophobia inability tolerate confinement small place would unable undergo MRI PET scan Part II Only : Has administer AChEI within prior 3 month require administration AChEI study Part III Only : Has administer galantamine within prior 7 day require administration galantamine study History within 2 year prior screen , current evidence neurological neurodegenerative disorder AD associate transient sustain alteration cognition History within 2 year prior screen , current evidence psychotic disorder major depressive disorder Part II III Only : Has suspect implant embedded metal object , fragment head body would present risk MRI scanning procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>